Genmab A/S (GMAB)

Market Cap	12.97B
Revenue (ttm)	2.97B
Net Income (ttm)	703.24M
Shares Out	63.51M
EPS (ttm)	10.80
PE Ratio	18.44
Forward PE	23.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,133,159
Open	20.22
Previous Close	20.09
Day's Range	20.13 - 20.43
52-Week Range	19.85 - 32.88
Beta	0.86
Analysts	Buy
Price Target	43.00 (+111.72%)
Earnings Date	Feb 12, 2025

About GMAB

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 2,204
• Stock Exchange: NASDAQ
• Ticker Symbol: GMAB
• Website: https://www.genmab.com

Financial Performance

In 2023, Genmab's revenue was 16.47 billion, an increase of 13.57% compared to the previous year's 14.51 billion. Earnings were 4.35 billion, a decrease of -20.18%.

Financial numbers in DKK

Analyst Forecast

According to 8 analysts, the average rating for GMAB stock is "Buy." The 12-month stock price forecast is $43.0, which is an increase of 111.72% from the latest price.

Price Target

$43.0

(111.72% upside)

Analyst Consensus: Buy